Martine A. Rothblatt
CHAIRPERSON & CEO at United Therapeutics Corporation
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: United Therapeutics Corporation, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
United Therapeutics Corporation June 26, 202695.3%
-
United Therapeutics Corporation June 26, 202593.7%
-
United Therapeutics Corporation June 26, 202493.5%
-
United Therapeutics Corporation June 26, 202395.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 9, 2026 | United Therapeutics Corporation | Option exercise | +9,500 | $117.76 | $1,118,720 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −494 | $583.80 | $288,398 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −80 | $556.52 | $44,522 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −840 | $584.70 | $491,148 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −161 | $558.07 | $89,849 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −280 | $585.63 | $163,975 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −168 | $558.70 | $93,862 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −71 | $559.80 | $39,746 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −517 | $561.15 | $290,114 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −512 | $562.35 | $287,923 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −291 | $563.49 | $163,976 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −160 | $564.36 | $90,298 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −220 | $565.56 | $124,423 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −300 | $566.57 | $169,972 |
| Nov 9, 2026 | United Therapeutics Corporation | Open-market sale | −400 | $567.48 | $226,992 |
Questions about Martine A. Rothblatt
What boards is Martine A. Rothblatt on?
Martine A. Rothblatt sits on the boards of Beta Technologies Inc. and United Therapeutics Corporation.
What company is Martine A. Rothblatt the CEO of?
Martine A. Rothblatt is CHAIRPERSON & CEO of United Therapeutics Corporation.
How long has Martine A. Rothblatt served on boards?
Our records show at least 5 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.